Program overview
Context
Indication: Lung Cancer
Mechanism: Unknown
Modality: Unknown
Sponsor: UNC Lineberger Comprehensive Cancer Center
Registry Stop Signal
erlotinib hydrochloride
erlotinib hydrochloride is flagged as registry stop signal because public records show a registry stop signal, operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.
Scores
Risk-signal summary
Registry: 5/5
Timeline: 1/5
Recruitment burden: 2/5
Results availability: 0/5
Program risk: 4/5
Evidence
Public links
https://clinicaltrials.gov/study/NCT00283244 | https://clinicaltrials.gov/study/NCT01259089 | https://clinicaltrials.gov/study/NCT00573989 | https://clinicaltrials.gov/study/NCT00087269 | https://clinicaltrials.gov/study/NCT00754494
Linked trials
Trial-level signal details
| Trial | Status | Timeline | Results | Burden |
|---|---|---|---|---|
| NCT00283244 | Low Signal (COMPLETED) | stale_update_signal | Low Signal | strict_eligibility_signal |
| NCT01259089 | Low Signal (COMPLETED) | stale_update_signal | Low Signal | rare_population_signal | strict_eligibility_signal |
| NCT00573989 | Registry Stop Signal (TERMINATED) | stale_update_signal | Low Signal | strict_eligibility_signal |
| NCT00087269 | Registry Stop Signal (TERMINATED) | stale_update_signal | Low Signal | strict_eligibility_signal |
| NCT00754494 | Low Signal (COMPLETED) | stale_update_signal | Low Signal | strict_eligibility_signal |